EligibleTrials

Randomized Withdrawal Study in Patients With Schizophrenia

Recruiting · NCT06961968 · Interventional (participants receive a specific treatment) · Lead sponsor: Vanda Pharmaceuticals

View the official record on ClinicalTrials.gov →
Schizophrenia

Interventions studied

iloperidoneplacebo

What this trial is about

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

Who can take part

Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

22 locations listed across 12 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.